{"schemaVersion":"1.0","generatedFrom":"https://brightaifuture.com/discoveries/eagle-esophageal-ct","record":{"id":"eagle-esophageal-ct","headline":"CT scans may carry a second clue.","canonicalUrl":"https://brightaifuture.com/discoveries/eagle-esophageal-ct","datePublished":"2026-09-25","dateModified":null,"sourcePublicationDate":"2026-09-22","author":null,"publisher":{"name":"Bright AI Future","url":"https://brightaifuture.com/"},"topics":["biology"],"summary":"A peer-reviewed study tested whether EAGLE, an AI system, could flag esophageal cancer on non-contrast chest CT scans people received for other reasons.","evidenceState":"Demonstrated","keyFacts":[{"label":"AI’s role","value":"A deep-learning system analyzed non-contrast chest CT scans for signs of esophageal cancer and high-grade intraepithelial neoplasia, including scans acquired for other reasons."},{"label":"Documented result","value":"Across 11,466 patients at eight external centres, EAGLE flagged 90.0% of known cancers (sensitivity) and correctly left 98.5% of patients without cancer unflagged (specificity). It flagged 60.1% of stage I cancers and 52.5% of precancerous lesions. In a separate prospective cohort of 17,446 patients at one hospital, it flagged 87.8% of known cancers. Of 90 alerts, 38 were confirmed malignant—36 cancers and two high-grade intraepithelial neoplasias—so 42.2% of alerts were confirmed malignant (positive predictive value)."},{"label":"Important limitation","value":"The prospective cohort had incomplete follow-up: among 52 people without confirmed malignancy, 28 had other findings, 19 were negative or had no symptoms, and five were lost to follow-up."}],"limitations":["The prospective cohort had incomplete follow-up: among 52 people without confirmed malignancy, 28 had other findings, 19 were negative or had no symptoms, and five were lost to follow-up.","The 10,959-person low-dose CT cohort was retrospective and single-site. Eight people were flagged, one cancer was confirmed, and five did not undergo endoscopy, so its 12.5% positive predictive value is not a complete screening outcome.","External sensitivity for stage I cancer was 60.1% and for precancerous lesions was 52.5%; the study does not show reduced mortality or better patient outcomes.","The authors call for broader international validation. DAMO Academy (Hupan Lab) was the main funder, and eight authors reported Alibaba employment and stock compensation."],"evidenceLinks":[{"title":"Large-scale esophageal cancer screening through noncontrast computed tomography and artificial intelligence · Nature Medicine","url":"https://www.nature.com/articles/s41591-026-04656-4","type":"paper"}],"evidencePackUrl":"https://brightaifuture.com/evidence-pack/eagle-esophageal-ct","embedUrl":"https://brightaifuture.com/embed/story/eagle-esophageal-ct","attribution":{"credit":"Bright AI Future","requirements":["Link to the canonical Bright record.","Keep material limitations with the claim they qualify.","Link to the original evidence when repeating a substantive claim.","Do not describe a source check or organization-reported result as independent verification."],"sourceRights":"Linked source material, quotations, trademarks and media remain subject to their owners’ terms. No reuse right is granted for third-party media."}},"claim":{"humanProblem":"Esophageal cancer is often difficult to see on ordinary chest CT and can be diagnosed after disease has advanced.","priorConstraint":"Chest CT scans taken for other reasons contain the esophagus, but subtle lesions can be overlooked and endoscopy is not performed for everyone.","aiRole":"A deep-learning system analyzed non-contrast chest CT scans for signs of esophageal cancer and high-grade intraepithelial neoplasia, including scans acquired for other reasons.","documentedResult":"Across 11,466 patients at eight external centres, EAGLE flagged 90.0% of known cancers (sensitivity) and correctly left 98.5% of patients without cancer unflagged (specificity). It flagged 60.1% of stage I cancers and 52.5% of precancerous lesions. In a separate prospective cohort of 17,446 patients at one hospital, it flagged 87.8% of known cancers. Of 90 alerts, 38 were confirmed malignant—36 cancers and two high-grade intraepithelial neoplasias—so 42.2% of alerts were confirmed malignant (positive predictive value).","whyItMayMatter":"If broader validation supports it, opportunistic review could draw attention to a hard-to-see disease on CT scans people already receive, without adding another scan.","unresolvedQuestions":["Will performance hold across more countries, cancer subtypes, scanners and care settings?","Can a complete follow-up pathway show whether alerts lead to earlier diagnosis and better outcomes without excessive procedures?","How should clinicians manage uncertain positives and precancerous lesions?"]},"evidenceAssessment":{"state":"Demonstrated","claimConfidence":"high","reviewState":"approved","reviewMethod":"ai-assisted","reviewNote":"Owner-authorized AI-assisted publication after primary-source comparison; claims, dates and material limitations remain bounded to the cited source.","lastSourceReview":"2026-09-25","independentVerification":"not-established-by-this-source-review"},"sources":[{"id":"source:eagle-esophageal-ct","title":"Large-scale esophageal cancer screening through noncontrast computed tomography and artificial intelligence · Nature Medicine","url":"https://www.nature.com/articles/s41591-026-04656-4","type":"paper"}],"revisions":[{"id":"revision:f53e5b3e0c9053ae7b7f","recordedAt":"2026-09-25","summary":"Published “CT scans may carry a second clue.” with its source date, evidence state and material limitations explicit.","sourceIds":["source:eagle-esophageal-ct"]}],"corrections":[]}